Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 3/2023

18-11-2022 | Stroke | Letter

GLP1RAs vs SGLT2is were associated with lower risk of major adverse limb events and similar risks of heart failure hospitalisation and stroke?

Authors: Lixin Du, Pan Wang, Hongwei Chen, Yu Zhang, Jianlan Ma

Published in: Diabetologia | Issue 3/2023

Login to get access

Excerpt

To the Editor: Lin and colleagues performed a real-world study [1] aiming to evaluate the risks of major adverse cardiovascular and limb events in people with diabetes treated with glucagon-like peptide-1 receptor agonists (GLP1RAs) vs sodium–glucose cotransporter 2 inhibitors (SGLT2is). The authors concluded that in people with diabetes, GLP1RAs were associated with significantly reduced risks of major adverse limb events (MALE) compared with SGLT2is. Moreover, this relative effectiveness was especially obvious in patients with diabetic neuropathy [1]. These findings are interesting and clinically relevant, but we want to share some additional comments. …
Literature
1.
2.
3.
4.
Sattar N, Lee M, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653–662. https://​doi.​org/​10.​1016/​S2213-8587(21)00203-5
5.
6.
Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573. https://​doi.​org/​10.​1136/​bmj.​m4573CrossRef
7.
8.
9.
Metadata
Title
GLP1RAs vs SGLT2is were associated with lower risk of major adverse limb events and similar risks of heart failure hospitalisation and stroke?
Authors
Lixin Du
Pan Wang
Hongwei Chen
Yu Zhang
Jianlan Ma
Publication date
18-11-2022
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2023
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-022-05835-x

Other articles of this Issue 3/2023

Diabetologia 3/2023 Go to the issue

Letter

Utility of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies: a viewpoint from the FDA

Article

Gene expression profiling in NOD mice reveals that B cells are highly educated by the pancreatic environment during autoimmune diabetes

Article

The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes

Article

Kidney function measures and cardiovascular outcomes in people with diabetes: the Hoorn Diabetes Care System cohort

Article

Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering

Article

Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits